Total Revenue
Johnson & Johnson Total Revenue decreased by 2.0% to $24.06B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 9.9%, from $21.89B to $24.06B. Over 4 years (FY 2021 to FY 2025), Total Revenue shows relatively stable performance with a 0.1% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase indicates growing market demand or successful price increases, while a decrease suggests market saturation or competitive pressure.
Detailed definition
The total amount of income generated by the sale of goods or services related to the company's primary operations. For a...
Peer comparison
Peer technology firms typically report this as Net Sales or Total Revenue, reflecting the scale of their market reach.
total_revenueHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $23.31B | $23.34B | $24.80B | $23.43B | $24.02B | $23.79B | $19.94B | $20.89B | $21.52B | $21.35B | $21.40B | $21.38B | $22.45B | $22.47B | $22.52B | $21.89B | $23.74B | $23.99B | $24.56B | $24.06B |
| QoQ Change | — | +0.1% | +6.3% | -5.6% | +2.5% | -1.0% | -16.2% | +4.8% | +3.0% | -0.8% | +0.2% | -0.1% | +5.0% | +0.1% | +0.2% | -2.8% | +8.5% | +1.1% | +2.4% | -2.0% |
| YoY Change | — | — | — | — | +3.0% | +1.9% | -19.6% | -10.8% | -10.4% | -10.3% | +7.3% | +2.3% | +4.3% | +5.2% | +5.3% | +2.4% | +5.8% | +6.8% | +9.1% | +9.9% |
Product Breakdown
| Segment | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| DARZALEX | $2.88B | $3.02B | $3.08B | $3.24B | $3.54B | $3.67B | $3.90B | $3.96B |
| Other | $305.00M | $292.00M | $281.00M | $323.00M | $309.00M | $264.00M | $249.00M | $2.90B |
| Tremfya | $906.00M | $1.01B | $949.00M | $956.00M | $1.19B | $1.42B | $1.59B | $1.61B |
| GENERAL | $1.35B | $1.33B | $1.36B | $1.32B | $1.39B | $1.38B | $1.47B | $1.39B |
| ADVANCED | $1.14B | $1.11B | $1.15B | $1.07B | $1.16B | $1.17B | $1.18B | $1.12B |
| INVEGASUSTENNAXEPLIONTRINZATREVICTA | $1.05B | $1.05B | $1.06B | $903.00M | $992.00M | $929.00M | $986.00M | $1.04B |
| CONTACTLENSESOTHER | $918.00M | $968.00M | $937.00M | $919.00M | $965.00M | $1.02B | $1.01B | $969.00M |
| ERLEADA | $736.00M | $790.00M | $784.00M | $771.00M | $908.00M | $936.00M | $959.00M | $949.00M |
| TRAUMA | $759.00M | $761.00M | $764.00M | $772.00M | $768.00M | $793.00M | $813.00M | $833.00M |
| SPINEOTHER | $743.00M | $696.00M | — | $671.00M | $727.00M | $698.00M | — | $694.00M |
| IMBRUVICA | $770.00M | $753.00M | $731.00M | $709.00M | $735.00M | $695.00M | $684.00M | $660.00M |
| Stelara | $2.89B | $2.68B | $2.35B | $1.63B | $1.65B | $1.57B | $1.23B | $656.00M |
| Simponi Simponi Aria | $537.00M | $516.00M | $583.00M | $659.00M | $690.00M | $687.00M | $632.00M | $647.00M |
| Xarelto | $587.00M | $592.00M | $676.00M | $690.00M | $621.00M | $635.00M | $687.00M | $642.00M |
| OPSUMIT/OPSYNVI(2) | — | — | — | $522.00M | $582.00M | $578.00M | — | $606.00M |
| CARVYKTI | $186.00M | $286.00M | $334.00M | $369.00M | $439.00M | $524.00M | $555.00M | $597.00M |
| UPTRAVI | $426.00M | $458.00M | $465.00M | $451.00M | $476.00M | $484.00M | $491.00M | $483.00M |
| SPRAVATO | $271.00M | $284.00M | $297.00M | $320.00M | $414.00M | $459.00M | $503.00M | $468.00M |
| PREZISTAPREZCOBIXREZOLSTASYMTUZA | $438.00M | $449.00M | $407.00M | $403.00M | $396.00M | $397.00M | $383.00M | $443.00M |
| HIPS | $417.00M | $381.00M | $418.00M | $409.00M | $421.00M | $405.00M | $439.00M | $436.00M |
| Remicade | $393.00M | $419.00M | $359.00M | $467.00M | $455.00M | $476.00M | $370.00M | $422.00M |
| KNEES | $394.00M | $352.00M | $398.00M | $389.00M | $389.00M | $377.00M | $432.00M | $420.00M |
| EDURAN Trilpivirine | $297.00M | $330.00M | $322.00M | $358.00M | $360.00M | $385.00M | $383.00M | $409.00M |
| SURGICAL | $367.00M | $333.00M | $365.00M | $361.00M | $403.00M | $383.00M | $411.00M | $396.00M |
| CAPLYTA | — | — | — | — | $211.00M | $240.00M | $249.00M | $270.00M |
| OTHERNEUROSCIENCE | $294.00M | $281.00M | $255.00M | $277.00M | $270.00M | $256.00M | $245.00M | $262.00M |
| RYBREVANT + LAZCLUZE | — | — | — | $141.00M | $179.00M | $198.00M | $216.00M | $257.00M |
| Tecvayli | $135.00M | $135.00M | $146.00M | $151.00M | $166.00M | $177.00M | $176.00M | $202.00M |
| Other Oncology | $221.00M | $250.00M | $282.00M | $89.00M | $93.00M | $94.00M | $100.00M | $192.00M |
| TALVEY | — | — | — | $86.00M | $106.00M | $122.00M | $149.00M | $152.00M |
| CONCERTA Methylphenidate | $163.00M | $142.00M | $159.00M | $148.00M | $164.00M | $140.00M | $132.00M | $136.00M |
| Other Immunology | $2.00M | $1.00M | $0.00 | $1.00M | $8.00M | $12.00M | $40.00M | $46.00M |
| Other Infectious Diseases | $61.00M | $55.00M | $45.00M | $41.00M | $47.00M | $47.00M | $40.00M | $37.00M |
| Abiomed | — | — | $374.00M | — | — | — | $437.75M | — |
| COVID-19 | $172.00M | $1.00M | $0.00 | — | — | — | — | — |
| ELECTROPHYSIOLOGY | — | — | $1.32B | — | — | — | $1.41B | — |
| OPSUMIT | $544.00M | $571.00M | $545.00M | — | — | — | $581.25M | — |
| other cardiovascular | — | — | — | — | — | — | $99.25M | — |
| SPINE,SPORTS & OTHER | — | — | $731.50M | — | — | — | $713.00M | — |
| ZYTIGA | $165.00M | $150.00M | $135.00M | $125.00M | $145.00M | $113.00M | $119.00M | — |
| Total | $22.45B | $22.47B | $22.52B | $21.89B | $23.74B | $23.99B | $24.56B | $24.06B |
Abiomed, ELECTROPHYSIOLOGY, other cardiovascular, Other Interventional Solutions, SPINE,SPORTS & OTHER are derived from annual filings.
Baby Care, COVID-19, OPSUMIT, Oral Care, Other Interventional Solutions, RISPERDALCONSTA, Womens Health, Wound Careand Other, ZYTIGA were previously reported and have since been discontinued or reclassified. Only currently active segments are shown in the chart.
Business Segments
| Segment | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Innovative Medicine | $14.49B | $14.58B | $14.33B | $13.87B | $15.20B | $15.56B | $15.76B | $15.43B |
| Medical Devices | $7.96B | $7.89B | $8.19B | $8.02B | $8.54B | $8.43B | $8.80B | $8.64B |
| Total | $22.45B | $22.47B | $22.52B | $21.89B | $23.74B | $23.99B | $24.56B | $24.06B |
Consumer, Pharmaceutical were previously reported and have since been discontinued or reclassified. Only currently active segments are shown in the chart.
Geographic Breakdown
| Segment | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Europe | $5.21B | $4.91B | $4.92B | $5.11B | $5.39B | $5.44B | $5.60B | $5.85B |
| Asia Pacific Africa | $3.45B | $3.48B | $3.26B | $3.31B | $3.61B | $3.61B | $3.50B | $3.59B |
| Western Hemisphere Excluding US | $1.21B | $1.17B | $1.14B | $1.17B | $1.21B | $1.23B | $1.27B | $1.29B |
| Total | $22.45B | $22.47B | $22.52B | $21.89B | $23.74B | $23.99B | $24.56B | $24.06B |
Total Revenue at Other Companies
Frequently Asked Questions
- What is Johnson & Johnson's total revenue?
- Johnson & Johnson (JNJ) reported total revenue of $24.06B in Q1 2026.
- How has Johnson & Johnson's total revenue changed year-over-year?
- Johnson & Johnson's total revenue increased by 9.9% year-over-year, from $21.89B to $24.06B.
- What is the long-term trend for Johnson & Johnson's total revenue?
- Over 4 years (2021 to 2025), Johnson & Johnson's total revenue has grown at a 0.1% compound annual growth rate (CAGR), from $93.78B to $94.19B.
- What does total revenue mean?
- The total amount of money a company brings in from selling its products and services.